Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sandostatin
Pharma
Chiasma posts data on benefits of oral acromegaly drug
Chiasma has released phase 3 data supporting its belief that acromegaly patients will prefer to take its oral formulation over injectables.
Nick Paul Taylor
Mar 23, 2021 9:35am
Sandostatin LAR can steer clear of generics in 2020: Novartis
Feb 3, 2020 11:28am
Novartis offloads endocrine drugs to Recordati for $390M
Jul 15, 2019 12:25pm
Novartis wins FDA nod for newly acquired cancer drug Lutathera
Jan 26, 2018 3:10pm
With latest buy, Novartis snags drug with $2B sales potential
Oct 30, 2017 11:00am
Klick brings tiny, trash-talking wrestler to new Novartis work
Jul 12, 2017 7:49am
